Molecule Information
General Information of the Molecule (ID: Mol01322)
Name |
KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1)
,Homo sapiens
|
||||
---|---|---|---|---|---|
Synonyms |
KCNQ1OT1
Click to Show/Hide
|
||||
Molecule Type |
LncRNA
|
||||
Gene Name |
FOXF1-AS1, lincFOXF1, onco-lncRNA-21
|
||||
Gene ID | |||||
Location |
chr11:2608328-2699994[-]
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
Cisplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Tongue cancer | [1] | |||
Resistant Disease | Tongue cancer [ICD-11: 2B62.0] | |||
Resistant Drug | Cisplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
Ezrin/FAKT/Src signaling pathway | Activation | hsa05205 | ||
In Vitro Model | CAL27 cells | Oral | Homo sapiens (Human) | CVCL_1107 |
SCC9 cells | Tongue | Homo sapiens (Human) | CVCL_1685 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Microarray; RT-PCR | |||
Experiment for Drug Resistance |
MTS assay; EdU assay; Flow cytometric analysis | |||
Mechanism Description | KCNQ1OT1 promotes TSCC cell proliferation and chemo-resistance via the regulation of miR-211-5p mediated Ezrin/Fak/Src signaling. |
Oxaliplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Hepatocellular carcinoma | [2] | |||
Resistant Disease | Hepatocellular carcinoma [ICD-11: 2C12.2] | |||
Resistant Drug | Oxaliplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Cell viability | Activation | hsa05200 | ||
miR7-5p/ABCC1 signaling pathway | Regulation | hsa05206 | ||
In Vitro Model | Huh-7 cells | Liver | Homo sapiens (Human) | CVCL_0336 |
HepG2 cells | Liver | Homo sapiens (Human) | CVCL_0027 | |
SMMC7721 cells | Uterus | Homo sapiens (Human) | CVCL_0534 | |
Skhep1 cells | Liver | Homo sapiens (Human) | CVCL_0525 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Overexpression of kCNQ1OT1 enhances OXA resistance through downregulating miR-7-5p and upregulating ABCC1 in HCC cells. |
Disease- and Tissue-specific Abundances of This Molecule
ICD Disease Classification 02
Liver cancer [ICD-11: 2C12]
Differential expression of molecule in resistant diseases | ||
The Studied Tissue | Bile duct | |
The Specified Disease | Cholangiocarcinoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 2.53E-03; Fold-change: -6.92E-01 | |
Molecule expression in the diseased tissue of patients
Molecule expression in the normal tissue of healthy individuals
|
||
Disease-specific Molecule Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Liver | |
The Specified Disease | Liver hepatocellular carcinoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 6.11E-24; Fold-change: 4.15E-01 | |
Molecule expression in the diseased tissue of patients
Molecule expression in the normal tissue of healthy individuals
|
||
Disease-specific Molecule Abundances | Click to View the Clearer Original Diagram | |
Tissue-specific Molecule Abundances in Healthy Individuals
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.